Clasificación en acciones
#28269
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to... Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Precio por acción
$0.0183374
Capitalización bursátil
$27.51M
Comercio Syntara Limited (SNT)
Ingresos de Syntara Limited (SNT)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Syntara Limited, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Syntara Limited desde 2026 hasta 2026
Ingresos al final de cada año
| Año |
Ingresos |
Cambiar |
|
Not enough data for the provided dates. |
Ingresos de empresas similares o competidoras
| Empresa |
Ingresos |
Diferencia de ingresos |
País |
|
|
- |
-
|
DE
|
|
|
- |
-
|
DE
|
|
|
- |
-
|
JP
|
|
|
- |
-
|
CH
|
|
|
$6.61B |
-
|
IN
|
